



Drug Information Bulletin

Pharmacist

Day

25th

September

Drug Information Centre (DIC)

Indian Pharmaceutical Association

Bengal Branch

Tele fax: 033 24612776, E-mail: ipabengal.dic@gmail.com

Web Site: <http://www.ipabengal.org>

Contact: 09830136291

&

Regulatory Affairs Division (RAD), IPA

Volume: 12

Number: 13

23rd September 2018

Content

- Editorial
- Message from Sri J.P.Nadda, Union Health Minister, Govt. of India on the eve of "Pharmacists Day"
- USFDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia
- Forthcoming event

Editorial

Wishing you all a happy "Pharmacists Day" in advance!

It has been noticed that the Ministry of Health and Family Welfare, Government of India is publishing advertisement seeking application for the "National Florence Nightingale Nurses Award" to recognize meritorious services of Nurses working in the State, Central, Autonomous Institutions, Private, Missionary and Voluntary organization in India. This award is being given on 12th May every year to recognize the service of a Nurse in India, which will in turn encourage other Nurses. Similar award is given to recognize doctors on 1st July every year, which will encourage doctors to serve the society better. Though two important health providers are being recognized, very unfortunately the third important health providers – "Pharmacists" are ignored till date.

A few years back Her Excellency Mrs. Pratiba Patil, President of India, in a programme at New Delhi declared that similar award will be given to the Pharmacist to recognize their contribution to the health care system. Unfortunately that has not happened till date. It may be due to bureaucratic delay or may be lack of persuasion by the pharmaceutical Organizations.

It is high time that all pharmaceutical organizations be united and pursues the matter. Hope we will see a similar advertisement seeking recommendation for such an award to be conferred during "Pharmacist Day"-25th September. Pharmacy Council of India has initiated step in this matter but yet to be implemented.

Dr. Subhash C. Mandal

Editor

E mail: subhash.mandaldr@gmail.com

Mob. 9830136291



Message from Sri J.P.Nadda, Union Health Minister, Government of India on the eve of "Pharmacists Day"



जगत प्रकाश नड्डा
Jagat Prakash Nadda



स्वास्थ्य एवं परिवार कल्याण मंत्री
भारत सरकार
Minister of Health & Family Welfare
Government of India

संकेत चिह्न

संकेत चिह्न

MESSAGE

I am happy to know that Pharmacists Day is being observed on the 25th September, 2018 with the theme "Pharmacist: Your Medicines Experts"

The role of pharmacist in research and innovation, manufacturing of quality medicines, distribution and dispensing of medicines to promote health, wellness, and disease prevention in co-operation with other members of inter-professional health team is highly appreciated.

I congratulate the Pharmacy Council of India for having developed globally competent pharmacist human resources who are effectively participating in strengthening the healthcare services in the country. I extend my best wishes to all the pharmacists of the country and hope that they will continue to serve the society.


(Jagat Prakash Nadda)


348, ए-विंग, निरमान भवन, नई दिल्ली-110 011
348, A-Wing, Nirman Bhawan, New Delhi-110 011
Tele. : (O) : +91-11-23061661, 23063513, Telefax : 23062358, 23061648
E-mail : hfminister@gov.in



Pharmacy Council of India
(A statutory body under the Ministry of Health & Family Welfare, Govt. of India)

**CELEBRATING
PHARMACISTS DAY
25th SEPTEMBER**

"Pharmacists: Your Medicines Experts"



Research and Innovation by:
Discovering and Developing new Drugs and Devices.

Manufacture of Quality Medicines
Using the latest technology so as to lower the cost of medicine.

Support and Young pharmacy
Young pharmacy on the current pharmaceutical and help them to...

Helping Healthcare Professionals
Supporting Healthcare Professionals...

Action and Direction
Protect Health and Prevent Illness

Enforcing Law and Regulations by:
Regulating the manufacture, distribution, sales and import of medicines and medical devices.

Providing Primary and Community Health Care by:
Facilitating public health campaigns in local communities.

Distribution and Dispensing of Medicines by:
Ensuring that the right medicines, at the right dose and at the right time are dispensed to the patients.

WHAT IS PHARMACISTS DAY?
It's a day to celebrate the one million registered pharmacists in India who work hard to keep the society healthy. As most of these pharmacists work silently behind the scene, there arises a need to recognize their hard work and contribution to the society. Most of the people are unaware of the range of services offered by pharmacists and know them as a person who simply dispenses medicines. Pharmacy Council of India encourages pharmacists to use this day to organise activities that promote and advocate for the role of the pharmacist in improving health in every corner of the world.

PHARMACISTS: YOUR MEDICINES EXPERTS
"Pharmacists: Your medicines experts" is the theme of this year's Pharmacists Day. The extensive expertise that pharmacists have are put to use every day to ensure better patient health. This expertise is through science and research, through educating generation, and through transforming patient new services. Pharmacists are a trusted source of knowledge and advice, not only for patients but also for healthcare professionals. For every patient who into a pharmacy, pharmacists ensure that the medicine is provided at the right dose and in the suitable formulation. Pharmacists work with healthcare professionals to ensure that every patient receives optimal treatment. Moreover, as one of the accessible health care professional globally, Pharmacists use their learning to protect health and prevent illness.

Pharmacists of India partner with Government of India for developing "Swachh and Swasth Bharat"

Visit: <http://www.pci.nic.in>

USFDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia

The U.S. Food and Drug Administration today approved Vyxeos for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of chemotherapy drugs daunorubicin and cytarabine.

"This is the first approved treatment specifically for patients with certain types of high-risk AML," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "Vyxeos combines two commonly used chemotherapies into a single formulation that may help some patients live longer than if they were to receive the two therapies separately."

AML is a rapidly progressing cancer that forms in the bone marrow and results in an increased number of white blood cells in the bloodstream. The National Cancer Institute at the National Institutes of Health estimates that approximately 21,380 people will be diagnosed with AML this year; approximately 10,590 patients with AML will die of the disease in 2017. T-AML occurs as a complication of chemotherapy or radiation in approximately 8 to 10 percent of all patients treated for cancer within an average of five years after treatment. AML-MRC is characterized by a history of certain blood disorders and other significant mutations within cancer cells. Patients with t-AML or AML-MRC have very low life expectancies.

The safety and efficacy of Vyxeos were studied in 309 patients with newly diagnosed t-AML or AML-MRC who were randomized to receive Vyxeos or separately administered treatments of daunorubicin and cytarabine. The trial measured how long patients lived from the date they

Did you know that....

**PHARMACIST DAY
25th September**

Your PHARMACIST is the vital link between you and your doctor in taking care of your health.

Your PHARMACIST is much more than a medicine seller.

Your PHARMACIST is a competent, professionally qualified expert, who can help you derive maximum benefits from your medicines.

**Know Your Medicines
Talk to Your PHARMACIST**

Pharmacists: Your Medicines Experts

Indian Pharmaceutical Association | www.ipapharma.org



started the trial (overall survival). Patients who received Vyxeos lived longer than patients who received separate treatments of daunorubicin and cytarabine (median overall survival 9.56 months vs. 5.95 months).

Common side effects of Vyxeos include bleeding events (hemorrhage), fever with low white blood cell count (febrile neutropenia), rash, swelling of the tissues (edema), nausea, inflammation of the mucous membranes (mucositis), diarrhea, constipation, musculoskeletal pain, fatigue, abdominal pain, shortness of breath (dyspnea), headache, cough, decreased appetite, abnormal heart rhythm (arrhythmia), lung infection (pneumonia), blood infection (bacteremia), chills, sleep disorders and vomiting.

Patients who have a history of serious hypersensitivity to daunorubicin, cytarabine or any component of the formulation should not use Vyxeos. Patients taking Vyxeos should be monitored for hypersensitivity reactions and decreased cardiac function. Vyxeos has been associated with serious or fatal bleeding events. Daunorubicin has been associated with severe damage (necrosis) where the drug leaks into the skin and subcutaneous tissue from the intravenous infusion (extravasation). Women who are pregnant or breastfeeding should not take

DISCLAIMER:

The Newsletter intends to provide updated and reliable information on medicines and other related issues in an attempt to equip healthcare professionals to take informed decision in recommending medicines to the patients. However, they are encouraged to validate the contents. None of the people associated with the publication of the Newsletter nor the organization shall be responsible for any liability for any damage incurred as a result of use of contents of this publication. The brand names of medicines, if mentioned, are for illustration only and the Newsletter does not endorse them.

Vyxeos, because it may cause harm to a developing fetus or a newborn baby.

September 25, 2018

PHARMACIST DAY

Pharmacists: Your Medicines Experts

Issued in public interest by:
INDIAN PHARMACEUTICAL ASSOCIATION
www.ipapharma.org



The prescribing information for Vyxeos includes a boxed warning not to interchange Vyxeos with other daunorubicin- and/or cytarabine-containing products.

The FDA granted this application Priority Review and Breakthrough Therapy designations. Vyxeos also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

IPA, Bengal Branch celebrates "Pharmacists Day"

25th September 2018

- Interactive session at SLT Hall, N.R.S. Medical College & Hospital, Kolkata
- Silent Rally from Medical college to Park Circus Maidan, Kolkata